Fascin-1, Ezrin and Paxillin Contribute to the Malignant Progression and Are Predictors of Clinical Prognosis in Laryngeal Squamous Cell Carcinoma

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Gao, Wei ^a,b   Zhang, Chunming ^a,b   Feng, Yan ^a,b   Chen, Ganggang ^a   Wen, Shuxin ^a,b   Huangfu, Hui ^a,b   Wang, Binquan ^a,b  

^a SHANXI MEDICAL UNIVERSITY   (China)

^b Key Institute and Laboratory of Otolaryngology affiliated with Shanxi Province   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EZRIN; FASCIN; FASCIN 1; MESSENGER RNA; PAXILLIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CERVICAL LYMPH NODE; CONTROLLED STUDY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; LARYNGEAL SQUAMOUS CELL CARCINOMA; LARYNX CARCINOMA; LARYNX SURGERY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; TUMOR DIFFERENTIATION;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PAXILLIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84870272509     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050710     Document Type: Article

References (59)

1. Chu EA, Kim YJ (2008) Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am 41: 673-695, v.
2. Li LD, Rao KQ, Zhang SW, Lu FZ, Zou XN, (2002) Statistical analysis of data from 12 cancer registries in China, 1993-1997. BULLETIN OF CHINESE CANCER 11: 497-507 (in Chinese).
3. Jiang LZ, Wang P, Deng B, Huang C, Tang WX, et al. (2011) Overexpression of Forkhead Box M1 transcription factor and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Hum Pathol 42: 1185-1193.
4. Ji W, Guan C, Pan Z, (2008) Analysis of curative effects on laryngeal carcinoma patients in the northeast region of China. Acta Otolaryngol 128: 574-577.
5. Hermans R, (2006) Staging of laryngeal and hypopharyngeal cancer: value of imaging studies. Eur Radiol 16: 2386-2400.
6. Yamaguchi H, Condeelis J, (2007) Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochim Biophys Acta 1773: 642-652.
7. Gardel ML, Schneider IC, Aratyn-Schaus Y, Waterman CM, (2010) Mechanical integration of actin and adhesion dynamics in cell migration. Annu Rev Cell Dev Biol 26: 315-333.
8. Benitez-King G, Soto-Vega E, Ramirez-Rodriguez G, (2009) Melatonin modulates microfilament phenotypes in epithelial cells: implications for adhesion and inhibition of cancer cell migration. Histol Histopathol 24: 789-799.
9. Buda A, Pignatelli M, (2004) Cytoskeletal network in colon cancer: from genes to clinical application. Int J Biochem Cell Biol 36: 759-765.
10. Otto JJ, Kane RE, Bryan J, (1979) Formation of filopodia in coelomocytes: localization of fascin, a 58,000 dalton actin cross-linking protein. Cell 17: 285-293.
11. Jawhari AU, Buda A, Jenkins M, Shehzad K, Sarraf C, et al. (2003) Fascin, an actin-bundling protein, modulates colonic epithelial cell invasiveness and differentiation in vitro. Am J Pathol 162: 69-80.
12. Vignjevic D, Schoumacher M, Gavert N, Janssen KP, Jih G, et al. (2007) Fascin, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 67: 6844-6853.
13. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M, (2004) The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 67: 262-270.
14. Lee TK, Poon RT, Man K, Guan XY, Ma S, et al. (2007) Fascin over-expression is associated with aggressiveness of oral squamous cell carcinoma. Cancer Lett 254: 308-315.
15. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, et al. (2005) Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 11: 2597-2605.
16. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, et al. (2003) Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer. Br J Cancer 88: 537-547.
17. Al-Alwan M, Olabi S, Ghebeh H, Barhoush E, Tulbah A, et al. (2011) Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLOS ONE 6: e27339.
18. Durmaz A, Kurt B, Ongoru O, Karahatay S, Gerek M, Yalcin S, (2010) Significance of fascin expression in laryngeal squamous cell carcinoma. J Laryngol Otol 124: 194-198.
19. Zou J, Yang H, Chen F, Zhao H, Lin P, et al. (2010) Prognostic significance of fascin-1 and E-cadherin expression in laryngeal squamous cell carcinoma. Eur J Cancer Prev 19: 11-17.
20. Tsukita S, Yonemura S, (1997) ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr Opin Cell Biol 9: 70-75.
21. Mackay DJ, Esch F, Furthmayr H, Hall A, (1997) Rho- and rac-dependent assembly of focal adhesion complexes and actin filaments in permeabilized fibroblasts: an essential role for ezrin/radixin/moesin proteins. J Cell Biol 138: 927-938.
22. Mangeat P, Roy C, Martin M, (1999) ERM proteins in cell adhesion and membrane dynamics. Trends Cell Biol 9: 187-192.
23. Mhawech-Fauceglia P, Dulguerov P, Beck A, Bonet M, Allal AS, (2007) Value of ezrin, maspin and nm23-H1 protein expressions in predicting outcome ofpatients with head and neck squamous-cell carcinoma treated with radicalradiotherapy. J Clin Pathol 60: 185-189.
24. Akisawa N, Nishimori I, Iwamura T, Onishi S, Hollingsworth MA, (1999) High levels of ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun 258: 395-400.
25. Chen Z, Fadiel A, Feng Y, Ohtani K, Rutherford T, Naftolin F, (2001) Ovarian epithelial carcinoma tyrosine phosphorylation, cell proliferation, and ezrin translocation are stimulated by interleukin 1alpha and epidermal growth factor. Cancer 92: 3068-3075.
26. Sarrio D, Rodriguez-Pinilla SM, Dotor A, Calero F, Hardisson D, et al. (2006) Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat 98: 71-79.
27. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M, (2005) The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res 7: R365-373.
28. Xie JJ, Xu LY, Wu ZY, Zhao Q, Xu XE, et al. (2011) Prognostic implication of ezrin expression in esophageal squamous cell carcinoma. J Surg Oncol 104: 538-543.
29. Zhu J, Feng Y, Ke Z, Yang Z, Zhou J, et al. (2012) Down-Regulation of miR-183 Promotes Migration and Invasion of Osteosarcoma by Targeting Ezrin. Am J Pathol 180: 2440-2451.
30. Deng X, Tannehill-Gregg SH, Nadella MV, He G, Levine A, et al. (2007) Parathyroid hormone-related protein and ezrin are up-regulated in human lung cancer bone metastases. Clin Exp Metastasis 24: 107-119.
31. Zhang XQ, Chen GP, Wu T, Yan JP, Zhou JY, (2012) Expression and clinical significance of ezrin in non-small-cell lung cancer. Clin Lung Cancer 13: 196-204.
32. Turner CE, (2000) Paxillin and focal adhesion signalling. Nat Cell Biol 2: E231-236.
33. Metalli D, Lovat F, Tripodi F, Genua M, Xu SQ, et al. (2010) The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am J Pathol 176: 2997-3006.
34. Cai HX, Yang LC, Song XH, Liu ZR, Chen YB, et al. (2012) Expression of paxillin and FAK mRNA and the related clinical significance inesophageal carcinoma. Mol Med Report 5: 469-472.
35. Li BZ, Lei W, Zhang CY, Zhou F, Li N, et al. (2008) Increased expression of paxillin is found in human oesophageal squamous cell carcinoma: a tissue microarray study. J Int Med Res 36: 273-278.
36. Li HG, Xie DR, Shen XM, Li HH, Zeng H, et al. (2005) Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 11: 1445-1451.
37. Wu DW, Cheng YW, Wang J, Chen CY, Lee H, (2010) Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 70: 10392-10401.
38. Shi J, Wang S, Zhao E, Shi L, Xu X, et al. (2010) Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma. J Oral Pathol Med 39: 548-551.
39. Dai Y, Pierson SE, Dudney WC, Stack BC Jr, (2010) Extraribosomal function of metallopanstimulin-1: reducing paxillin in head and neck squamous cell carcinoma and inhibiting tumor growth. Int J Cancer 126: 611-619.
40. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, et al. (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 60: 4693-4696.
41. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
42. Kim SJ, Choi IJ, Cheong TC, Lee SJ, Lotan R, et al. (2010) Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 138: 1035-1045.e1-2.
43. Goncharuk VN, Ross JS, Carlson JA, (2002) Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol 29: 430-438.
44. Hashimoto Y, Skacel M, Adams JC, (2005) Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker. Int J Biochem Cell Biol 37: 1787-1804.
45. Liu R, Liao J, Yang M, Sheng J, Yang H, et al. (2012) The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLOS ONE 7: e33987.
46. Curado MP, Hashibe M, (2009) Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol 21: 194-200.
47. Nowak JM, Grzanka A, Gagat M, Zuryn A, (2009) The influence of cotinine on the non-small-cell lung cancer line A549. Postepy Hig Med Dosw (Online) 63: 1-7.
48. Hunter KW, (2004) Ezrin, a key component in tumor metastasis. Trends Mol Med 10: 201-204.
49. Wang YY, Chen WL, Huang ZQ, Yang ZH, Zhang B, et al. (2011) Expression of the membrane-cytoskeletal linker Ezrin in salivary gland adenoidcystic carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 112: 96-104.
50. Wang L, Lin GN, Jiang XL, Lu Y, (2011) Expression of ezrin correlates with poor prognosis of nasopharyngeal carcinoma. Tumour Biol 32: 707-712.
51. Yeh CN, Pang ST, Chen TW, Wu RC, Weng WH, et al. (2009) Expression of ezrin is associated with invasion and dedifferentiation ofhepatitis B related hepatocellular carcinoma. BMC Cancer 9: 233.
52. Kobel M, Langhammer T, Huttelmaier S, Schmitt WD, Kriese K, et al. (2006) Ezrin expression is related to poor prognosis in FIGO stage I endometrioidcarcinomas. Mod Pathol 19: 581-587.
53. Sattler M, Pisick E, Morrison PT, Salgia R, (2000) Role of the cytoskeletal protein paxillin in oncogenesis. Crit Rev Oncog 11: 63-76.
54. Schaller MD, (2001) Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20: 6459-6472.
55. Athanasopoulou A, Aroukatos P, Nakas D, Repanti M, Papadaki H, et al. (2011) Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression. Urol Oncol (In press).
56. Mackinnon AC, Tretiakova M, Henderson L, Mehta RG, Yan BC, et al. (2011) Paxillin expression and amplification in early lung lesions of high-riskpatients, lung adenocarcinoma and metastatic disease. J Clin Pathol 64: 16-24.
57. Conway WC, Van der Voort van Zyp J, Thamilselvan V, Walsh MF, Crowe DL, et al. (2006) Paxillin modulates squamous cancer cell adhesion and is important inpressure-augmented adhesion. J Cell Biochem 98: 1507-1516.
58. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, et al. (2008) Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 68: 132-142.
59. Schenk P, (1977) [Cytoplasmic microfilaments in laryngeal carcinoma malignant keratinocytes(author's transl)]. HNO 25: 413-418.